Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

4370 results

Sort By:

NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis

Study ID: NCT04129515
Start Date: 2025-10-30
End Date: 2027-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

30

Intervention / Treatment

NovoTTF-200A

Pembrolizumab

Sponsor

Brown University

Source: clinicaltrials.gov

Share:
Add to list

Normobaric Oxygen Therapy in Colorectal Cancer Patients

Study ID: NCT06946004
Start Date: 2025-11-01
End Date: 2028-11-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

254

Intervention / Treatment

Normobaric oxygen therapy

Normobaric oxygen therapy

Sponsor

4th Military Clinical Hospital with Polyclinic, Poland

Source: clinicaltrials.gov

Share:
Add to list

Cranial Nerve Functions in Behçet's Disease and Their Relationship With Clinical Parameters

Study ID: NCT07135063
Start Date: 2025-10
End Date: 2026-09
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

60

Intervention / Treatment
Sponsor

Marmara University

Source: clinicaltrials.gov

Share:
Add to list

Result Of Karyotyping in Pediatric Patients With Congenital Anomalies and Developmental Delay

Study ID: NCT07167017
Start Date: 2025-11-01
End Date: 2026-12
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

75

Intervention / Treatment
Sponsor

Assiut University

Source: clinicaltrials.gov

Share:
Add to list

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

Study ID: NCT06860815
Start Date: 2025-12-12
End Date: 2027-01-03
Study Type

Interventional

Study Phase

Phase2

No. of Participants

11

Intervention / Treatment

Biopsy

Biospecimen Collection

Cemiplimab

Computed Tomography

Magnetic Resonance Imaging

Transarterial Radioembolization

Yttrium Y 90 Resin Microspheres

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease

Study ID: NCT07178678
Start Date: 2025-11
End Date: 2030-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

90

Intervention / Treatment

Neuroepo

Placebo

Sponsor

University of Saskatchewan

Source: clinicaltrials.gov

Share:
Add to list

Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow Function

Study ID: NCT07169825
Start Date: 2026-02-13
End Date: 2028-09-01
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

25

Intervention / Treatment

Lu-177

SPECT

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab

Study ID: NCT06876714
Start Date: 2025-10-25
End Date: 2037-03-13
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1524

Intervention / Treatment

Trastuzumab (Herceptin)

Pertuzumab

Echocardiography

Multigated Acquisition Scan

Mammography

Ultrasound

Magnetic Resonance Imaging

Biospecimen Collection

Administration questionnaire

Sponsor

Alliance for Clinical Trials in Oncology

Source: clinicaltrials.gov

Share:
Add to list

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Study ID: NCT04008121
Start Date: 2025-11
End Date: 2026-05
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

10

Intervention / Treatment

Fluorescein sodium and Zeiss FF450 fundus camera

MB-102 and Zeiss FF450 fundus camera

Fluorescein sodium and commercially available optical angiography imaging system

MB-102 and commercially available optical angiography imaging system

Sponsor

MediBeacon

Source: clinicaltrials.gov

Share:
Add to list

Optimal Antiplatelet Therapy in Patients After Coronary Artery Bypass Grafting. (OPTIMUS-CABG Trial)

Study ID: NCT07195149
Start Date: 2025-10-31
End Date: 2030-11-30
Study Type

Interventional

Study Phase

Phase3

No. of Participants

1703

Intervention / Treatment

High-Dose Aspirin 300 mg

DAPT (Low-Dose Aspirin 75 mg + Prasugrel 10 mg)

Low-Dose Aspirin 75 mg

Sponsor

Lower Silesian Center of Heart Diseases. Zbigniew Religa Medinet Sp. z o.o.

Source: clinicaltrials.gov

Share:
Add to list